Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41706578.
- Also identified by DOI 10.1093/infdis/jiaf459 and PMC identifier 13016734.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Using an established pharmacokinetic/pharmacodynamic tissue model of tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis (PrEP), we predict that adding a fourth day of dosing to the 3-day IPERGAY on-demand PrEP regimen (currently approved for men/transgender women who have sex with men) will be efficacious for on-demand dosing in cisgender women.
Medical subject headings
- HIV Infections
- Pre-Exposure Prophylaxis
- Anti-HIV Agents
- Emtricitabine
- Tenofovir